Your browser doesn't support javascript.
loading
Signaling through FcγRIIA and the C5a-C5aR pathway mediates platelet hyperactivation in COVID-19
Sokratis A. Apostolidis; Amrita Sarkar; Heather M. Giannini; Rishi R. Goel; Divij Mathew; Aae Suzuki; Amy E. Baxter; Allison R. Greenplate; Cecile Alanio; Mohamed Abdel-Hakeem; Derek A. Oldridge; Josephine R. Giles; Jennifer E. Wu; Zeyu Chen; Yinghui Jane Huang; Ajinkya Pattekar; Sasikanth Manne; Oliva Kuthuru; Jeanette Dougherty; Brittany Weiderhold; Ariel R. Weisman; Caroline A.G. Ittner; Sigrid Gouma; Debora Dunbar; Ian Frank; Alexander C. Huang; Laura A. Vella; - The UPenn COVID Processing Unit; John P. Reilly; Scott E. Hensley; Lubica Rauova; Liang Zhao; Nuala J. Meyer; Mortimer Poncz; Charles S. Abrams; E John Wherry.
Afiliação
  • Sokratis A. Apostolidis; University of Pennsylvania
  • Amrita Sarkar; University of Pennsylvania
  • Heather M. Giannini; University of Pennsylvania
  • Rishi R. Goel; University of Pennsylvania
  • Divij Mathew; University of Pennsylvania
  • Aae Suzuki; University of Pennsylvania
  • Amy E. Baxter; University of Pennsylvania
  • Allison R. Greenplate; University of Pennsylvania
  • Cecile Alanio; University of Pennsylvania
  • Mohamed Abdel-Hakeem; University of Pennsylvania
  • Derek A. Oldridge; University of Pennsylvania
  • Josephine R. Giles; University of Pennsylvania
  • Jennifer E. Wu; University of Pennsylvania
  • Zeyu Chen; University of Pennsylvania
  • Yinghui Jane Huang; University of Pennsylvania
  • Ajinkya Pattekar; University of Pennsylvania
  • Sasikanth Manne; University of Pennsylvania
  • Oliva Kuthuru; University of Pennsylvania
  • Jeanette Dougherty; University of Pennsylvania
  • Brittany Weiderhold; University of Pennsylvania
  • Ariel R. Weisman; University of Pennsylvania
  • Caroline A.G. Ittner; University of Pennsylvania
  • Sigrid Gouma; University of Pennsylvania
  • Debora Dunbar; University of Pennsylvania
  • Ian Frank; University of Pennsylvania
  • Alexander C. Huang; University of Pennsylvania
  • Laura A. Vella; University of Pennsylvania
  • - The UPenn COVID Processing Unit; -
  • John P. Reilly; University of Pennsylvania
  • Scott E. Hensley; University of Pennsylvania
  • Lubica Rauova; University of Pennsylvania
  • Liang Zhao; University of Pennsylvania
  • Nuala J. Meyer; University of Pennsylvania
  • Mortimer Poncz; University of Pennsylvania
  • Charles S. Abrams; University of Pennsylvania
  • E John Wherry; University of Pennsylvania
Preprint em En | PREPRINT-BIORXIV | ID: ppbiorxiv-442279
ABSTRACT
Patients with COVID-19 present with a wide variety of clinical manifestations. Thromboembolic events constitute a significant cause of morbidity and mortality in patients infected with SARS-CoV-2. Severe COVID-19 has been associated with hyperinflammation and pre-existing cardiovascular disease. Platelets are important mediators and sensors of inflammation and are directly affected by cardiovascular stressors. In this report, we found that platelets from severely ill, hospitalized COVID-19 patients exhibit higher basal levels of activation measured by P-selectin surface expression, and have a poor functional reserve upon in vitro stimulation. Correlating clinical features to the ability of plasma from COVID-19 patients to stimulate control platelets identified ferritin as a pivotal clinical marker associated with platelet hyperactivation. The COVID-19 plasma-mediated effect on control platelets was highest for patients that subsequently developed inpatient thrombotic events. Proteomic analysis of plasma from COVID-19 patients identified key mediators of inflammation and cardiovascular disease that positively correlated with in vitro platelet activation. Mechanistically, blocking the signaling of the Fc{gamma}RIIa-Syk and C5a-C5aR pathways on platelets, using antibody-mediated neutralization, IgG depletion or the Syk inhibitor fostamatinib, reversed this hyperactivity driven by COVID-19 plasma and prevented platelet aggregation in endothelial microfluidic chamber conditions, thus identifying these potentially actionable pathways as central for platelet activation and/or vascular complications in COVID-19 patients. In conclusion, we reveal a key role of platelet-mediated immunothrombosis in COVID-19 and identify distinct, clinically relevant, targetable signaling pathways that mediate this effect. These studies have implications for the role of platelet hyperactivation in complications associated with SARS-CoV-2 infection. Cover illustration O_FIG_DISPLAY_L [Figure 1] M_FIG_DISPLAY C_FIG_DISPLAY One-sentence summaryThe Fc{gamma}RIIA and C5a-C5aR pathways mediate platelet hyperactivation in COVID-19
Licença
cc_by_nc_nd
Texto completo: 1 Coleções: 09-preprints Base de dados: PREPRINT-BIORXIV Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2021 Tipo de documento: Preprint
Texto completo: 1 Coleções: 09-preprints Base de dados: PREPRINT-BIORXIV Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2021 Tipo de documento: Preprint